Merck signs $70 million deal to commercialize Abbisko's new

Merck has entered into a $70 million licensing agreement with Abbisko Therapeutics for pimicotinib, which is currently being evaluated in a phase 3 study for the treatment of tenosynovial giant cell tumor (TGCT).

Related Keywords

Macau , China , Taiwan , Hong Kong , Andrew Paterson , Xu Yao Chang , European Medicines Agency , China National Medical Products Administration , Drug Administration , Abbisko Therapeutics , Markets Amp Regulations , Lobalization , Linical Evolution , Merck , Dancer , Ncology ,